|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Tenecteplase#Use in Specific Populations]] |
| {{Tenecteplase}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| ==Use In Specific Populations==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ===Pregnancy (Category C)===
| |
| | |
| TNKase has been shown to elicit maternal and embryo toxicity in rabbits given multiple IV administrations. In rabbits administered 0.5, 1.5, and 5.0 mg/kg/day, [[vaginal hemorrhage]]resulted in maternal deaths. Subsequent embryonic deaths were secondary to maternal hemorrhage and no fetal anomalies were observed. TNKase does not elicit maternal and embryo toxicity in rabbits following a single IV administration. Thus, in developmental toxicity studies conducted in rabbits, the no observable effect level (NOEL) of a single IV administration of TNKase on maternal or developmental toxicity was 5 mg/kg (approximately 8–10 times the human dose). There are no adequate and well‑controlled studies in pregnant women. TNKase should be given to pregnant women only if the potential benefits justify the potential risk to the fetus.
| |
| | |
| ===Nursing Mothers===
| |
| | |
| It is not known if TNKase is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TNKase is administered to a nursing woman.
| |
| | |
| ===Pediatric Use===
| |
| | |
| The safety and effectiveness of TNKase in pediatric patients have not been established.
| |
| | |
| ===Geriatric Use===
| |
| | |
| Of the patients in ASSENT-2 who received TNKase, 4,958 (59%) were under the age of 65; 2,256 (27%) were between the ages of 65 and 74; and 1,244 (15%) were 75 and over. The 30-day mortality rates by age were 2.5% in patients under the age of 65, 8.5% in patients between the ages of 65 and 74, and 16.2% in patients age 75 and over. The ICH rates were 0.4% in patients under the age of 65, 1.6% in patients between the ages of 65 and 74, and 1.7% in patients age 75 and over. The rates of any stroke were 1.0% in patients under the age of 65, 2.9% in patients between the ages of 65 and 74, and 3.0% in patients age 75 and over. Major bleeding rates, defined as bleeding requiring blood transfusion or leading to hemodynamic compromise, were 3.1% in patients under the age of 65, 6.4% in patients between the ages of 65 and 74, and 7.7% in patients age 75 and over. In elderly patients, the benefits of TNKase on mortality should be carefully weighed against the risk of increased adverse events, including bleeding.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TNKASE (TENECTEPLASE) KIT [GENENTECH, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=69e391bf-1250-4083-aa60-6aa41c33657f | publisher = | date = | accessdate = 6 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Thrombolytic drugs]]
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |